BMYCelgeneFinished
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 503 (final count)
- Started
- Apr 1, 2014
- Main results expected
- May 11, 2024
- Fully finished
- Sep 17, 2024
- Results posted
- Jul 10, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: From the first dose date of maintenance therapy to objective disease progression or death from any cause, whichever occurs first (up to approximately 432 weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT01996865 · record last updated 2025-07-10 · checked 2026-11-09 15:47 UTC